Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fighting RNA viruses with a gold nanoparticle Cas13d gene-editing armor

17 Apr 2025

Abstract excerpt

A novel Cas13d-based gene-editing approach has been developed to target viral RNAs in infected cells, reducing the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Zika virus (ZIKV) by up to 90% compared with controls. Despite its potential, the use of Cas13d as an antiviral faces several challenges that limit its effectiveness before reaching target cells. This study presents a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Mosquito-borne diseases and control
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40391300
DOI: 10.1016/j.omtn.2025.102540

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fighting RNA viruses with a gold nanoparticle Cas13d gene-editing armorPMID 40391300Read ↗

Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitroSemantic proximity Read ↗

CRISPR/Cas13-Based Anti-RNA Viral ApproachesSemantic proximity Read ↗

CRISPR/Cas13-Based Anti-RNA Viral ApproachesSemantic proximity Read ↗

Engineering CRISPR/Cas13 System against RNA Viruses: From Diagnostics to TherapeuticsSemantic proximity Read ↗

Potent programmable antiviral against dengue virus in primary human cells by Cas13b RNP with short spacer and delivery by virus-like particleSemantic proximity Read ↗

Potent programmable antiviral against dengue virus in primary human cells by Cas13b RNP with short spacer and delivery by VLPSemantic proximity Read ↗

The CRISPR/Cas13 system edits viral spike and nucleocapsid RNA to resist SARS-CoV-2 infectionSemantic proximity Read ↗

Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeuticsSemantic proximity Read ↗

Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike proteinSemantic proximity Read ↗

CRISPR‐Cas13d effectively targets SARS‐CoV‐2 variants, including Delta and Omicron, and inhibits viral infectionSemantic proximity Read ↗

Detection of SARS-CoV-2 and Its Mutated Variants via CRISPR-Cas13-Based Transcription Amplification.Semantic proximity Read ↗

Potential of siRNA in COVID-19 therapy: Emphasis on in silico design and nanoparticles based deliverySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.